Clinical Trial Update: Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the safety and efficacy of autologous endothelial progenitor cell CD133 for therapeutic angiogenesis in coronary artery disease and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina
• Coronary Artery Disease

Drugs mentioned

• Autologous Endothelial Progenitor Cell CD133

Snippet

Sponsor: Pilar Jimenez Quevedo | Conditions: Coronary Artery Disease, Refractory Angina | Phase 1, Phase 2 | Status: COMPLETED